TAFRO综合征的诊治现状

Current status of TAFRO syndrome

TAFRO综合征以血小板减少、全身性水肿、骨髓纤维化、肾功能不全及器官肿大为特征性临床表现，急性或者亚急性起病。目前，该病发病机制尚未阐明，被认为是Castleman病的特殊亚型之一。由于TAFRO综合征的发病率低，病例报道少，目前临床医师对该病认识尚存在不足。早期发现、精确诊断、及时采取有效治疗措施，有利于提高TAFRO综合征患者的生存率。笔者总结了近年TAFRO综合征的诊治现状及研究进展，旨在帮助临床医师更好的理解。TAFRO综合征，以提高对该病的诊治水平。

TAFRO syndrome is characterized by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organ enlargement, which is acute or subacute onset. Its current etiopathogenisis remains unclear. It is considered to be a specific subtype of Castleman disease. Due to the low incidence and few case reports, there is not enough understanding of TAFRO syndrome. Early detection, accurate diagnosis, timely and effective treatments are the key points to improve the survival rate of patients with TAFRO syndrome. Here, this article summarizes the diagnosis and treatments of TAFRO syndrome and review the research progress. The goal of this article is to help clinicians have a better understanding of TAFRO syndrome, so that TAFRO syndrome can be diagnosed and treated in time.